A boutique venture capital firm manages an evergreen USD fund. The fund focuses on healthcare industry, generally participating in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $3-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.
The firm is most interested in biopharma, biotechnology, medical devices, artificial intelligence. Within medtech, the firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment